Programme

This year the digital Anglonordic programme brings you the opportunity to engage and participate in two Keynote sessions, four interactive panel discussions, company presentations, workshops, networking sessions and one-to-one partnering from the 25 - 28 May.


Tuesday 25 May 2021

Tuesday offers a series of Workshops, Networking and one-to-one partnering. Further details to be announced soon!

14:00     Finding Funding Workshop

During this webinar hosted by SEHTA you'll gain an overview of public sector funding opportunities: including how to write a successful grant application plus an overview of private sector funding opportunities: including how to produce an effective Investor Pitch slide deck.

Speakers: 

  • Dr David Parry, CEO, SEHTA
  • Nick Rodgers, Chair, SEHTA

Each webinar delegate will be given the opportunity to apply for a one hour 1:1 Funding Review with the SEHTA team. For further details and to register click here.


Wednesday 26 May 2021

09:00    Welcome

Mattias Johansson, The Anglonordic Life Science Conference Founder & Director of Ezenze


09:05     Keynote

Kate Bingham, Managing Partner, SV Health Investors


09:30     Panel Discussion: What's Hot? What's Simmering?

Europe’s leading investors will provide an overview of their outlook on the market, as well as current and future trends that are driving investment in the healthcare sector.

Chaired by: Amber Tong, Endpoints

Panellists:

  • Hakan Goker, M Ventures
  • Deborah Harland, SR One
  • Nanna Lüneborg, Novo Holdings
  • Stephan Christgau, EIR Ventures


10:30    Keynote

Dr Joern-Peter Halle, SVP, Global Head of Research, Healthcare, Merck Healthcare


11:00    Company Presentations

Biotech Investment and Technology Investment Company Presentations

Companies presenting include:

  • STORM Therapeutics, is a pioneer in the field of RNA epigenetics.
  • Adare Pharmaceuticals, a global, technology-driven CDMO providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets.
  • Myxobiotics, developing the cystobactamid broad-spectrum anti-bacterial for treatment of cUTI and possibly HAP/VAP.
  • Macrophage Pharma, focused on treating human disease by reprogramming macrophage function through transcriptional reprogramming and targeted drug-delivery leveraging proprietary Esterase Sensitive Motif™ (ESM™) platform.
  • Santersus, an Innovative Therapeutic Apheresis company focused on cleansing patient blood of neutrophil extracellular traps (NETs) looking to revolutionize how they can control the human immune and inflammatory response to disease.
  • VAXIMM, a privately held Swiss/German biotech company that is developing oral T-cell immunotherapies.
  • SNIPR BIOME, a CRISPR and Microbiome company focused on the interplay between life-threatening infectious diseases treatment and prevention, the microbiome and Oncology.
  • Gate2Brain, a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. 
  • Aortyx, a pioneer company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona that aims at providing a new generation of endovascular devices to treat vascular diseases. 
  • Indi Molecular, developing a breakthrough, fully synthetic protein chemistry platform to transform targeted therapeutic and molecular imaging.
  • Emenda Therapeutics, a new UK-based RNA-splicing biotech founded on the world-leading insight of its academic Founders in the field of splicing factor kinase inhibition. The company is developing novel small molecules to modulate aberrant mRNA splicing and bring forward new medicines for the treatment of chronic pain and cancer.


12:30    Networking Sessions

Informal opportunities throughout the programme to meet with other delegates, connect and build relationships.


13:00    Panel Discussion: DDR Therapeutics

A panel of industry experts and investors will discuss this exciting field of biology, clinically validated by the first-generation PARP inhibitors currently on the market. Listen to the panel discuss the strength of DNA Damage Response as an investment opportunity and how this hot area of biology will rapidly impact the clinic.

Chaired by: Lucie Ellis, In Vivo

Panellists:

  • Niall Martin, Artios Pharma
  • Mark O'Connor, AstraZeneca
  • Andree Blaukat, Merck KGaA
  • Simon Boulton, Artios Pharma & Francis Crick Institute


13:45    Company Presentations

Biotech Investment and Technology Investment Company Presentations

Apply to pitch here.


15:30    Panel Discussion: Building your Board - Structure, Diversity, Success

Join our panel of internationally experienced Board profiles from the industry as they discuss the importance of an agile, forward-looking, tenacious and diverse Board for success in the healthcare sector. Amongst them, our panel have experienced what an impactful Board looks like and the momentum it can give any growth stage life science business for success.

Chaired by: Maureen Coleman

Panellists:

  • Eva-Lotta Allan, Non-Executive Director and Chair
  • Patrick Vink, Non-Executive Chairman and Board Member
  • Melanie Lee, LifeArc
  • Edwin Moses, Independent Director


16:15    Panel Discussion: If I knew then what I know now

Mike Ward Chairs a panel of industry executives who will reflect on previous experiences and discuss key learnings from their careers.

Chaired by: Mike Ward

Panellists:

  • Roel Bulthuis, INKEF Capital
  • Steven Powell, eTheRNA immunotherapies
  • More to be announced soon!


17:15    Conclusions

Reflections on the days themes and topics.

Hosted by:

  • Hakan Goker, M Ventures
  • Mary Clark, Optimum Communications


17:30    Networking 

Hosted by Mattias Johansson and our Sponsors join our informal networking rooms to toast the end of an exciting day. 

More details to be announced soon!